Nanosizing--oral formulation development and biopharmaceutical evaluation.

By F. Kesisoglou, S. Panmai, Yunhui Wu. Advanced Drug Delivery Reviews, 2007

1,085 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Strategies to Address Low Drug Solubility in Discovery and Development (2013, methodology): “…allowed the administration of higher doses than were possible using a nonaqueous lipid formulation (750 versus 350 mg/kg) and subsequently led to significantly increased drug exposure in rats compared with both nonmicronized material and a lipid-surfactant mixture (Kesisoglou et al., 2007) (Fig.”
Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. (2008, methodology): “Nowadays, awareness of nanosuspensions as a formulation option is becoming more widespread throughout the pharmaceutical developmental chain with possible considerations in computational, toxicological, preclinical and clinical settings (Kesisoglou et al., 2007).”